S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

ALRN Aileron Therapeutics Inc

2.09

-0.19 (-8.33%)

Jan 06 2025 - Closed

Delayed by 15 minutes

Form ARS - Annual Report to Security Holders

Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Aileron Therapeutics Charts.

Aileron Therapeutics (NASDAQ:ALRN)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Aileron Therapeutics Charts.

Aileron Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Monday 9 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 6 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 4 December 2024 (1 month ago) • Edgar (US Regulatory)

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Thursday 14 November 2024 (2 months ago) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Wednesday 13 November 2024 (2 months ago) • PR Newswire (US)

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Thursday 31 October 2024 (2 months ago) • PR Newswire (US)

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Saturday 12 October 2024 (3 months ago) • PR Newswire (US)

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Monday 23 September 2024 (3 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 22 August 2024 (5 months ago) • Edgar (US Regulatory)

More Aileron Therapeutics Inc News Articles

Societe Generale Effekten

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions